Abstract: A solid oral dosage form of methylphenidate or salts thereof which provide a rapid initial onset of action and a prolonged duration of effect is provided. The solid oral dosage form comprises a matrix core containing methylphenidate or salts thereof coated by a modified release coating and an outer methylphenidate immediate release coating.

Abstract: An extended release aqueous suspension composition of methylphenidate or salts thereof is provided. The extended release aqueous suspension of methylphenidate or salts has pH of more than 5.0 and exhibits excellent storage stability when tested for impurity and potency of methylphenidate. The suspension also comprises immediate release and sustained release components of methylphenidate or salts thereof. Following administration of a single dose of the extended release aqueous suspension of methylphenidate, a therapeutically effective amount of methylphenidate is reached in less than an hour, provides a release profile of at least 12 hours and has an in vivo release characterized by one single main plasma concentration peak.

Abstract: An extended release aqueous suspension composition of methylphenidate or salts thereof, is provided. The extended release aqueous suspension of methylphenidate or salts has pH below 3.5 and exhibit excellent storage stability when tested for impurity and potency of methylphenidate. The suspension also comprises immediate release and sustained release components of methylphenidate or salts thereof. Following administration of a single dose of the extended release aqueous suspension of methylphenidate, a therapeutically effective amount of methylphenidate is reached in less than an hour, provides release profile of at least 12 hours and its vivo release is characterized by one single main plasma concentration peak.